Cargando…
ID4: a new player in the cancer arena
Id proteins (Id-1 to 4) are dominant negative regulators of basic helix-loop-helix transcription factors. They play a key role during development, preventing cell differentiation while inducing cell proliferation. They are poorly expressed in adult life but can be reactivated in tumorigenesis. Sever...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053547/ https://www.ncbi.nlm.nih.gov/pubmed/21293053 |
_version_ | 1782320389930614784 |
---|---|
author | Dell'Orso, Stefania Ganci, Federica Strano, Sabrina Blandino, Giovanni Fontemaggi, Giulia |
author_facet | Dell'Orso, Stefania Ganci, Federica Strano, Sabrina Blandino, Giovanni Fontemaggi, Giulia |
author_sort | Dell'Orso, Stefania |
collection | PubMed |
description | Id proteins (Id-1 to 4) are dominant negative regulators of basic helix-loop-helix transcription factors. They play a key role during development, preventing cell differentiation while inducing cell proliferation. They are poorly expressed in adult life but can be reactivated in tumorigenesis. Several evidences indicate that Id proteins are associated with loss of differentiation, unrestricted proliferation and neoangiogenesis in diverse human cancers. Recently, we identified Id4 as a transcriptional target of the protein complex mutant p53/E2F1/p300 in breast cancer. Id4 protein binds, stabilizes and enhances the translation of mRNAs encoding proangiogenic cytokines, such as IL8 and GRO-alpha, increasing the angiogenic potential of cancer cells. We present here an overview of the current experimental data that links Id4 to cancer. We provide evidence also of the induction of Id4 following anticancer treatments in mutant p53-carrying cells. Indeed, mutant p53 is recruited to a specific region of the Id4 promoter upon DNA damage. Our findings indicate that Id4, besides its proangiogenic role, might also participate in the chemoresistance associated to mutant p53 proteins exerting gain of function activities. |
format | Online Article Text |
id | pubmed-4053547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-40535472014-06-17 ID4: a new player in the cancer arena Dell'Orso, Stefania Ganci, Federica Strano, Sabrina Blandino, Giovanni Fontemaggi, Giulia Oncotarget Research Perspective Id proteins (Id-1 to 4) are dominant negative regulators of basic helix-loop-helix transcription factors. They play a key role during development, preventing cell differentiation while inducing cell proliferation. They are poorly expressed in adult life but can be reactivated in tumorigenesis. Several evidences indicate that Id proteins are associated with loss of differentiation, unrestricted proliferation and neoangiogenesis in diverse human cancers. Recently, we identified Id4 as a transcriptional target of the protein complex mutant p53/E2F1/p300 in breast cancer. Id4 protein binds, stabilizes and enhances the translation of mRNAs encoding proangiogenic cytokines, such as IL8 and GRO-alpha, increasing the angiogenic potential of cancer cells. We present here an overview of the current experimental data that links Id4 to cancer. We provide evidence also of the induction of Id4 following anticancer treatments in mutant p53-carrying cells. Indeed, mutant p53 is recruited to a specific region of the Id4 promoter upon DNA damage. Our findings indicate that Id4, besides its proangiogenic role, might also participate in the chemoresistance associated to mutant p53 proteins exerting gain of function activities. Impact Journals LLC 2010-05-01 /pmc/articles/PMC4053547/ /pubmed/21293053 Text en Copyright: © 2010 Dell'Orso et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Perspective Dell'Orso, Stefania Ganci, Federica Strano, Sabrina Blandino, Giovanni Fontemaggi, Giulia ID4: a new player in the cancer arena |
title | ID4: a new player in the cancer arena |
title_full | ID4: a new player in the cancer arena |
title_fullStr | ID4: a new player in the cancer arena |
title_full_unstemmed | ID4: a new player in the cancer arena |
title_short | ID4: a new player in the cancer arena |
title_sort | id4: a new player in the cancer arena |
topic | Research Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053547/ https://www.ncbi.nlm.nih.gov/pubmed/21293053 |
work_keys_str_mv | AT dellorsostefania id4anewplayerinthecancerarena AT gancifederica id4anewplayerinthecancerarena AT stranosabrina id4anewplayerinthecancerarena AT blandinogiovanni id4anewplayerinthecancerarena AT fontemaggigiulia id4anewplayerinthecancerarena |